Cocrystal Pharma Inc (COCP)

$1.24 +0.01 (0.81%)
Market Cap 23.89M
Revenue (ttm) 0.00
Net Income (ttm) -8.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 58,500
Avg Vol 56,340
Day's Range N/A - N/A
Shares Out 19.26M
Stochastic %K 74%
Beta 1.48
Analysts Strong Sell
Price Target $8.00

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 262 7123
Address:
19805 North Creek Parkway, Bothell, United States
Resurrect_Momentum2030
Resurrect_Momentum2030 Sep. 10 at 3:19 PM
$COCP Reminder New CEO Sapirstein said he expects this to be a billion dollar biotech very soon his words and sure got the street cred to prove sold his first biotech he founded for BILLIONS the fun has only just begun
1 · Reply
BULLSWIN75
BULLSWIN75 Sep. 9 at 5:25 PM
$COCP are ya’ll paying attention? 👀 https://stocks.apple.com/AgJgfznB5QW2O2eTZNJnVVg
0 · Reply
Ultimate1trader
Ultimate1trader Sep. 9 at 11:26 AM
$COCP News News News
0 · Reply
BULLSWIN75
BULLSWIN75 Sep. 9 at 12:13 AM
$COCP nice bump today.. could see this move above 2.00 before EOY study results are announced
0 · Reply
elon_musk22
elon_musk22 Sep. 8 at 11:12 AM
$COCP let's go baby! 🤡
0 · Reply
elon_musk22
elon_musk22 Sep. 8 at 11:12 AM
$COCP Nobody told this idiot to buy the covid highs 6 yrs ago and never sell look in the mirror MO-RON your the failed pumper
0 · Reply
BULLSWIN75
BULLSWIN75 Sep. 5 at 12:27 AM
$COCP https://finance.yahoo.com/healthcare/articles/cocrystal-pharma-strategic-reset-investors-153903604.html
1 · Reply
BULLSWIN75
BULLSWIN75 Sep. 2 at 3:15 PM
$COCP trial results before EoY:. 🔥
0 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 28 at 1:01 PM
$COCP #1 past pumper so embarrassing nobody told him not to sell ever but this is the same clown who owns black berry from 1990 and never sold he thinks returns are guaranteed idiot big mouth
0 · Reply
bulmar
bulmar Aug. 28 at 12:52 AM
$COCP Yeah I tried with this stock but all insiders do is sell and go away. Schinazi was disappointing because he fled this company quickly. After years of nothing getting done and false hope it ‘s on CoCrystal. They claim to have pan viral potential but can’t focus on one. The desperate moment was when they mentioned hantavirus. For God Sake quit chasing the shiny and get something done. Anything…. So far, the chart shows why you shouldn’t invest or go long. Shorts have killed it since inception. Poor Momo down 90 percent and has never made a dime with this stock yet he pumps incessantly.
0 · Reply
Latest News on COCP
Cocrystal Pharma doses last subject in norovirus challenge study

2026-09-09T11:26:07.000Z - 4 days ago

Cocrystal Pharma doses last subject in norovirus challenge study

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Sep 9, 2026, 7:00 AM EDT - 4 days ago

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Aug 17, 2026, 11:17 AM EDT - 27 days ago

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Cocrystal Pharma announces $5M investment from Opko Health

2026-08-03T11:25:21.000Z - 5 weeks ago

Cocrystal Pharma announces $5M investment from Opko Health

OPK

Cocrystal Pharma announces $5M private placement with Opko Health

2026-08-03T11:15:31.000Z - 5 weeks ago

Cocrystal Pharma announces $5M private placement with Opko Health

OPK

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Aug 3, 2026, 7:00 AM EDT - 5 weeks ago

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

2026-06-03T11:14:05.000Z - 3 months ago

Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

2026-05-26T12:20:21.000Z - 3 months ago

Cocrystal Pharma announces discovery of pan-viral inhibitors targeting viruses

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026, 8:00 AM EDT - 4 months ago

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Apr 30, 2026, 4:05 PM EDT - 4 months ago

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

Cocrystal Pharma files $150M mixed securities shelf

2026-04-23T23:25:20.000Z - 4 months ago

Cocrystal Pharma files $150M mixed securities shelf

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

2026-04-02T12:22:27.000Z - 5 months ago

Cocrystal Pharma receives FDA Fast Track designation for CDI-988

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

2026-03-09T12:10:09.000Z - 6 months ago

Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mar 9, 2026, 8:00 AM EDT - 6 months ago

First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Feb 19, 2026, 8:00 AM EST - 6 months ago

Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

2025-12-18T13:16:41.000Z - 8 months ago

Cocrystal Pharma receives IRB approval from Emory University for Phase 1b trial

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 18, 2025, 8:00 AM EST - 8 months ago

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Dec 1, 2025, 8:00 AM EST - 9 months ago

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

2025-11-14T13:11:15.000Z - 10 months ago

Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Nov 14, 2025, 8:00 AM EST - 10 months ago

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma completes $1.03M private placement

2025-10-30T12:26:32.000Z - 10 months ago

Cocrystal Pharma completes $1.03M private placement

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

2025-10-27T12:20:43.000Z - 10 months ago

Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Oct 2, 2025, 8:00 AM EDT - 11 months ago

Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

2025-09-19T20:35:11.000Z - 11 months ago

Cocrystal Pharma files to sell 5.74M shares of common stock for holders

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 15, 2025, 4:30 PM EDT - 12 months ago

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma announces up to $13M registered direct offering

2025-09-12T13:45:10.000Z - 1 year ago

Cocrystal Pharma announces up to $13M registered direct offering

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Sep 12, 2025, 9:43 AM EDT - 1 year ago

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

2025-09-12T12:10:38.000Z - 1 year ago

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Sep 12, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

2025-09-08T12:05:24.000Z - 1 year ago

Cocrystal Pharma receives IND clearance for challenge study of CDI-988

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

2025-08-14T12:15:44.000Z - 1 year ago

Cocrystal Pharma reports Q2 EPS (20c), consensus (30c)

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma presents Phase 1 results for CDI-988

2025-08-05T12:26:50.000Z - 1 year ago

Cocrystal Pharma presents Phase 1 results for CDI-988

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Jul 10, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

2025-06-20T10:10:30.000Z - 1 year ago

Cocrystal Pharma price target lowered to $6 from $7 at H.C. Wainwright

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 29, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 15, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Mar 6, 2025, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 19, 2024, 4:05 PM EDT - 2 years ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 3:00 PM EDT - 2 years ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 13, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

May 1, 2024, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Mar 5, 2024, 8:30 AM EST - 2 years ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Dec 6, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 27, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 9, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Apr 10, 2023, 8:30 AM EDT - 3 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 26, 2023, 8:00 AM EST - 3 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Resurrect_Momentum2030
Resurrect_Momentum2030 Sep. 10 at 3:19 PM
$COCP Reminder New CEO Sapirstein said he expects this to be a billion dollar biotech very soon his words and sure got the street cred to prove sold his first biotech he founded for BILLIONS the fun has only just begun
1 · Reply
BULLSWIN75
BULLSWIN75 Sep. 9 at 5:25 PM
$COCP are ya’ll paying attention? 👀 https://stocks.apple.com/AgJgfznB5QW2O2eTZNJnVVg
0 · Reply
Ultimate1trader
Ultimate1trader Sep. 9 at 11:26 AM
$COCP News News News
0 · Reply
BULLSWIN75
BULLSWIN75 Sep. 9 at 12:13 AM
$COCP nice bump today.. could see this move above 2.00 before EOY study results are announced
0 · Reply
elon_musk22
elon_musk22 Sep. 8 at 11:12 AM
$COCP let's go baby! 🤡
0 · Reply
elon_musk22
elon_musk22 Sep. 8 at 11:12 AM
$COCP Nobody told this idiot to buy the covid highs 6 yrs ago and never sell look in the mirror MO-RON your the failed pumper
0 · Reply
BULLSWIN75
BULLSWIN75 Sep. 5 at 12:27 AM
$COCP https://finance.yahoo.com/healthcare/articles/cocrystal-pharma-strategic-reset-investors-153903604.html
1 · Reply
BULLSWIN75
BULLSWIN75 Sep. 2 at 3:15 PM
$COCP trial results before EoY:. 🔥
0 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 28 at 1:01 PM
$COCP #1 past pumper so embarrassing nobody told him not to sell ever but this is the same clown who owns black berry from 1990 and never sold he thinks returns are guaranteed idiot big mouth
0 · Reply
bulmar
bulmar Aug. 28 at 12:52 AM
$COCP Yeah I tried with this stock but all insiders do is sell and go away. Schinazi was disappointing because he fled this company quickly. After years of nothing getting done and false hope it ‘s on CoCrystal. They claim to have pan viral potential but can’t focus on one. The desperate moment was when they mentioned hantavirus. For God Sake quit chasing the shiny and get something done. Anything…. So far, the chart shows why you shouldn’t invest or go long. Shorts have killed it since inception. Poor Momo down 90 percent and has never made a dime with this stock yet he pumps incessantly.
0 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 27 at 1:03 PM
$COCP Quit lying Exposed pumper BUL MAR jai wei couldn't stop bragging back then only a terrible person or hater wants investors 6 yrs later to FAIL like him
0 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 27 at 12:48 PM
$COCP Worth continuing to point out why clown BUL MAR jai wei tell Everyone about his past personal financial failures instead of blaming others? Its everyone else look over there not ME the #1 pumper exposed
0 · Reply
bulmar
bulmar Aug. 27 at 1:27 AM
$COCP Hey Ressurected dipshit you lied for 3 years. What happened to your 50 dollar price target in June. Bullshit flows when your mouth opens. Not to mention the 30 plus accounts you’ve admitted to having to spew garbage. You’re trash and paid. You bought at 10 dollars fool.
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 26 at 6:52 PM
$COCP lets keep the board clean and insults out.. Some are Bulls, some Bears… what matters is the clinical outcomes EOY on the drug candidate for Norovirus. If strong, i 100% bet this goes over 5+. If poor, then she sinks. The risk u take on a clinical stage biotech
0 · Reply
Resurrect_Momentum2030
Resurrect_Momentum2030 Aug. 26 at 1:04 PM
$COCP Worth pointing out BULMAR jai wei the clown who still knows nothing about the business the #1 past pumper like no other never sold covid stock loser on everything 6 yrs too early now wants new investors to be HIM no thanks!
0 · Reply
BULLSWIN75
BULLSWIN75 Aug. 25 at 5:36 PM
$COCP EOY study results will be here… 👀
0 · Reply
elon_musk22
elon_musk22 Aug. 24 at 5:43 PM
$COCP buckle up big surprise when you least expect
0 · Reply
elon_musk22
elon_musk22 Aug. 24 at 5:37 PM
$COCP Calling Roaring Douglas thank LOL god bankrupt doesn't manage money guaranteed to make 1000% only IF u always take the opposite Side of this losers trades his old account #1 lucid pumper 2000 posts 5 yrs removed for pumping fraud was a laughingstock & ouch even still LMFAO meanwhile game stop 7 to 500 lucid down 99.99% 🤡
0 · Reply
bulmar
bulmar Aug. 24 at 4:01 PM
$COCP As price goes up Martin will be collecting money from the shelf offering. Good times.
0 · Reply
DOUG_Called_It
DOUG_Called_It Aug. 24 at 2:19 PM
$COCP no need to worry, all under control… as expected
0 · Reply
elon_musk22
elon_musk22 Aug. 23 at 6:00 PM
$COCP 6 yrs ago pumper bulmar now this broke idiot owns 100 shares but still has the biggest mouth crybaby never sold STFU
0 · Reply
elon_musk22
elon_musk22 Aug. 23 at 5:58 PM
$COCP STFU bulmar idiot
0 · Reply